Title of article
Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial
Author/Authors
Jose Valdez Madruga، نويسنده , , Daniel Berger، نويسنده , , Marilyn McMurchie، نويسنده , , Fredy Suter، نويسنده , , Denes Banhegyi، نويسنده , , Kiat Ruxrungtham، نويسنده , , Dorece Norris، نويسنده , , Eric Lefebvre، نويسنده , , Marie-Pierre de Bethune، نويسنده , , Frank Tomaka، نويسنده , , Martine De Pauw، نويسنده , , Tony Vangeneugden، نويسنده , , Sabrina Spinosa-Guzman، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2008
Pages
10
From page
49
To page
58
Abstract
Background
The protease inhibitor darunavir has been shown to be efficacious in highly treatment-experienced patients with HIV infection, but needs to be assessed in patients with a broader range of treatment experience. We did a randomised, controlled, p
Journal title
The Lancet
Serial Year
2008
Journal title
The Lancet
Record number
591591
Link To Document